Skip to main content

Table 3 Sensitivity analyses

From: Drug eluting balloons for de novocoronary lesions – a systematic review and meta-analysis

Endpoint Confidence intervals Prediction intervals Only published data Without STEMI Only combined DEB+BMS Excluding progenitor cell stent DEB exclusively
MACE 0.95 (0.64 to 1.39) 0.95 (0.35 to 2.52) 0.95 (0.64 to 1.39) 0.84 (0.61 to 1.15) 0.84 (0.61 to 1.15) 0.95 (0.64 to 1.39) 1.07 (0.67 to 1.70)
TLR 1.09 (0.71 to 1.68) 1.09 (0.31 to 3.83) 0.97 (0.63 to 1.50) 1.01 (0.68 to 1.51) 1.00 (0.65 to 1.55) 1.20 (0.79 to 1.82) 1.18 (0.70 to 1.99)
Binary restenosis 0.96 (0.48 to 1.93) 0.96 (0.10 to 9.05) 0.96 (0.48 to 1.93) 0.77 (0.40 to 1.48) 0.82 (0.40 to 1.66) 1.18 (0.59 to 2.35) 1.20 (0.48 to 2.96)
MI 1.26 (0.49 to 3.21) 1.26 (0.13 to 11.83) 0.86 (0.40 to 1.85) 1.13 (0.42 to 3.06) 1.18 (0.43 to 3.24) 1.30 (0.46 to 3.65) 1.69 (0.62 to 4.59)
Mortality 0.79 (0.30 to 2.11) NA 0.58 (0.20 to 1.71) 0.78 (0.29 to 2.15) 0.76 (0.27 to 2.18) 0.88 (0.31 to 2.45) 0.93 (0.32 to 2.71)
ST 1.45 (0.42 to 5.01) NA 1.45 (0.42 to 5.01) 1.13 (0.29 to 4.40) 1.50 (0.41 to 5.57) 1.52 (0.41 to 5.63) 1.59 (0.40 to 6.36)
  1. BMS, bare metal stent; DEB, drug eluting balloon; MACE, major adverse cardiac events; MI, myocardial infarction; RR, relative risk (and 95% confidence intervals); ST, stent thrombosis; TLR, target lesion revascularization.